Fig. 5: MNK1/2 and mTORC1/2 pharmacological inhibition reduces T128 liver metastasis in vivo.
From: RAB1A is a novel vulnerability in uveal melanoma revealed by dual inhibition of MNK1/2 and mTOR
A Schematic overview of the splenic injection model using NCG mice injected with T128 luc-tdTomato; the tumor burden was determined by log10 luminoscore (photons/sec) acquired bi-weekly. NCG mice were treated with vehicle, SEL201 (75 mg/kg per day) and INK128 (0.5 mg/kg per day). B In vivo imaging of NCG bearing T128 luc-tdTomato tumors treated with vehicle (n = 6), SEL201 (n = 5), INK128 (n = 5) and combination treatments (n = 7), two-way ANOVA multiple comparisons test, ns=non-significant, *P ≤ 0.05 at day 17. C Ex vivo imaging of NCG with T128 luc-tdTomato metastases treated with vehicle (n = 6), SEL201 (n = 5), INK128 (n = 5) and combination treatments (n = 7), one-way ANOVA multiple comparisons test, ns=non-significant, *P ≤ 0.05. D–G Representative images and quantification of human nucleolin for metastasis area (detection using DAB), p-S6, p-eIF4E and RAB1A (detection using Magenta) IHC of NCG livers injected with T128 luc-tdTomato. One-way ANOVA multiple comparisons test, ns=non-significant, *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001 and ****P ≤ 0.0001. Areas noted in yellow correspond to T128 liver metastasis.
